Ono Pharmaceutical 미래 성장

Future 기준 확인 0/6

Ono Pharmaceutical 의 수익은 연간 10.2% 감소할 것으로 예상되는 반면, 연간 수익은 0.5% 로 증가할 것으로 예상됩니다. 0.5% 연간. EPS는 연간 9.7% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.2% 로 예상됩니다.

주요 정보

-10.2%

수익 성장률

-9.7%

EPS 성장률

Pharmaceuticals 수익 성장	21.6%
매출 성장률	0.5%
향후 자기자본 수익률	8.2%
애널리스트 커버리지	Good
마지막 업데이트	12 Aug 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

MUN:ON4 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (JPY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	515,323	78,336	75,181	117,258	9
3/31/2026	511,287	77,434	62,440	104,903	10
3/31/2025	480,057	74,657	-135,369	27,300	10
6/30/2024	500,331	120,953	105,249	121,111	N/A
3/31/2024	502,672	127,977	89,831	110,660	N/A
12/31/2023	498,070	127,611	91,301	106,044	N/A
9/30/2023	489,199	124,875	97,371	115,354	N/A
6/30/2023	460,481	115,064	98,429	116,894	N/A
3/31/2023	447,187	112,723	145,113	159,610	N/A
12/31/2022	428,951	111,555	137,391	149,495	N/A
9/30/2022	403,985	96,568	93,387	102,437	N/A
6/30/2022	380,720	85,922	78,395	88,151	N/A
3/31/2022	361,361	80,519	49,552	61,829	N/A
12/31/2021	345,781	73,558	38,233	53,343	N/A
9/30/2021	332,887	81,866	60,412	83,032	N/A
6/30/2021	321,734	78,003	47,401	70,321	N/A
3/31/2021	309,284	75,425	53,684	73,977	N/A
12/31/2020	302,054	74,364	53,088	72,011	N/A
9/30/2020	293,886	66,737	55,742	70,596	N/A
6/30/2020	293,351	64,870	58,824	78,232	N/A
3/31/2020	292,420	59,704	51,712	74,157	N/A
12/31/2019	290,736	60,233	43,202	73,947	N/A
9/30/2019	293,247	55,510	38,797	66,058	N/A
6/30/2019	291,374	52,633	32,152	58,850	N/A
3/31/2019	288,634	51,539	37,172	66,774	N/A
12/31/2018	284,463	51,978	42,500	67,269	N/A
9/30/2018	284,785	57,919	29,645	61,700	N/A
6/30/2018	272,165	53,746	16,591	48,716	N/A
3/31/2018	261,836	50,284	N/A	15,727	N/A
12/31/2017	256,522	54,760	N/A	28,754	N/A
9/30/2017	248,517	53,884	N/A	40,205	N/A
6/30/2017	246,953	53,887	N/A	53,650	N/A
3/31/2017	244,797	55,793	N/A	74,450	N/A
12/31/2016	236,710	48,270	N/A	44,743	N/A
9/30/2016	207,707	36,225	N/A	32,972	N/A
6/30/2016	183,345	29,206	N/A	16,805	N/A
3/31/2016	160,284	24,979	N/A	12,842	N/A
12/31/2015	140,927	16,449	N/A	29,716	N/A
9/30/2015	143,697	21,568	N/A	31,169	N/A
6/30/2015	139,663	19,521	N/A	30,488	N/A
3/31/2015	135,775	12,976	N/A	31,579	N/A
12/31/2014	137,592	17,663	N/A	N/A	N/A
9/30/2014	133,926	13,474	N/A	19,681	N/A
6/30/2014	137,146	16,787	N/A	N/A	N/A
3/31/2014	143,247	20,350	N/A	28,422	N/A
12/31/2013	145,946	21,574	N/A	N/A	N/A
9/30/2013	145,984	23,205	N/A	18,773	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ON4 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -10.2% ).

수익 vs 시장: ON4 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -10.2% ).

고성장 수익: ON4 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: ON4 의 수익(연간 0.5% ) German 시장( 5.6% 보다 느리게 성장할 것으로 예상됩니다. 5.6% 연간).

고성장 수익: ON4 의 수익(연간 0.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ON4 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 8.2 %).

Ono Pharmaceutical 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Ono Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Full year 2024 earnings released: EPS: JP¥267 (vs JP¥231 in FY 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

Upcoming dividend of JP¥40.00 per share

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings released: EPS: JP¥88.30 (vs JP¥67.30 in 2Q 2023)

Less than half of directors are independent

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings released: EPS: JP¥65.16 (vs JP¥60.37 in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 23% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings released: EPS: JP¥231 (vs JP¥162 in FY 2022)

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

Now 25% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견